Last reviewed · How we verify
NCT04981691: Amaretto
Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors
Phase 1 trial testing anti-MESO CAR T cells in Refractory Malignant Solid Neoplasm in 12 participants. Status unknown.
9 January 2022
Quick facts
| Lead sponsor | Ruijin Hospital |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 1 October 2021 |
| Primary completion | 9 January 2022 |
| Estimated completion | 9 July 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- anti-MESO CAR T cells
Conditions studied
- Refractory Malignant Solid Neoplasm — all drugs for Refractory Malignant Solid Neoplasm →
Sponsor
Ruijin Hospital
Who can join
Adults 18 to 80, any sex, with Refractory Malignant Solid Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to study the safety, efficacy, and pharmacokinetics of mRNA-engineered anti-Mesothelin (MESO) Chimeric Antigen Receptor T-Cell (CAR-T cells) therapy in patients with mesothelin expression-positive, advanced solid tumors that have failed at least first-line or second-line therapy.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion.
Gumber D, Wang LD. · · 2022 · cited 276× · PMID 35301179 · DOI 10.1016/j.ebiom.2022.103941 -
Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment.
Yan T, Zhu L, Chen J. · · 2023 · cited 132× · PMID 36707873 · DOI 10.1186/s40164-023-00373-7 -
Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy.
Liu Z, Zhou Z, Dang Q, Xu H, et al · · 2022 · cited 124× · PMID 36168626 · DOI 10.7150/thno.76854 -
mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications.
Wang YS, Kumari M, Chen GH, Hong MH, et al · · 2023 · cited 93× · PMID 37805495 · DOI 10.1186/s12929-023-00977-5 -
Challenges of Anti-Mesothelin CAR-T-Cell Therapy.
Zhai X, Mao L, Wu M, Liu J, et al · · 2023 · cited 47× · PMID 36900151 · DOI 10.3390/cancers15051357 -
Navigating the intricate in-vivo journey of lipid nanoparticles tailored for the targeted delivery of RNA therapeutics: a quality-by-design approach.
Haghighi E, Abolmaali SS, Dehshahri A, Mousavi Shaegh SA, et al · · 2024 · cited 28× · PMID 39543630 · DOI 10.1186/s12951-024-02972-w -
Cancer stem cells: a target for overcoming therapeutic resistance and relapse.
Zhang S, Yang R, Ouyang Y, Shen Y, et al · · 2024 · cited 20× · PMID 38164743 · DOI 10.20892/j.issn.2095-3941.2023.0333 -
Enhancing CAR T-cell therapies against solid tumors: Mechanisms and reversion of resistance.
Qin Y, Xu G. · · 2022 · cited 18× · PMID 36569859 · DOI 10.3389/fimmu.2022.1053120
Verify or expand the search:
- PubMed search for NCT04981691
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Refractory Malignant Solid Neoplasm
Currently open trials in the same condition.
- NCT06911008 — MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers · Phase 1 · recruiting
- NCT06620302 — Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Soli · Phase 1, PHASE2 · recruiting
- NCT06223542 — Studying TAK-243 in Patients With Advanced Cancer · Phase 1 · recruiting
- NCT06320405 — Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Sol · Phase 1, PHASE2 · recruiting
- NCT05554341 — Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatm · Phase 2 · active not recruiting
Other Ruijin Hospital trials
Trials by the same sponsor.
- NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors · not yet recruiting
- NCT07449507 — Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy · NA · not yet recruiting
- NCT07496385 — Clinical Study on the Efficacy of Subglottic Suction in Mechanically Ventilated Patients Guided by Bedside Ultrasound · NA · not yet recruiting
- NCT07511114 — A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyp · Phase 3 · not yet recruiting
- NCT07514169 — The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04981691 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ruijin Hospital
- Last refreshed: 17 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04981691.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing